A Multi-center, Randomized, Double-blinded, Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease.

A Multi-center, Randomized, Double-blinded, Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease.

Completed

Phase of Trial:
Phase III

Latest Information Update:16 Nov 2016

At a glance

Drugs
Adalimumab (Primary)

Indications
Crohn's disease; Fistula

Focus
Registrational; Therapeutic Use

Acronyms
IMAgINE 1; IMAgINE-1

Sponsors
Abbott Laboratories

Most Recent Events

19 May 2016
Results from this trial will be presented at the Digestive Disease Week (DDW) Annual Meeting 2016, according to an AbbVie media release.

02 May 2016
This trial is prematurely ended in Italy.

04 Apr 2016
Results published in an AbbVie media release.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login
with a username/password associated to an account with a valid subscription